Actively Recruiting
Observational Study of Aflibercept Using a Paediatric Dosing Device in Preterm Infants with Retinopathy of Prematurity in the UK
Led by Bayer · Updated on 2026-10-20
200
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are observing how the drug aflibercept Eylea is used to treat preterm babies with retinopathy of prematurity ROP in the United Kingdom. ROP is an eye condition affecting premature infants, especially those born before 32 weeks of pregnancy or weighing less than 1.5 kilograms, which can lead to vision problems or blindness. This study aims to determine how many babies receive aflibercept using a paediatric dosing device PDD and to collect data on patient characteristics and disease features. The study collects data only from preterm babies treated with aflibercept 0.4 mg administered via a prefilled syringe PFS combined with a paediatric dosing device PDD. This drug-device combination is approved for treating babies with ROP. Data will be gathered from the National Neonatal Research Database covering babies born from March 2024 to March 2025, or up to April 2027 if more data are needed. No new treatments, visits, or tests are required for study participation since it is observational. Participants existing medical data are reviewed to count how many babies received the treatment and to describe their age, sex, race, and clinical signs. Researchers will analyze outcomes including maternal factors, comorbidities, resource use, and ocular disease information up to three years after the drugs market introduction. The study does not involve active interventions and will monitor data until April 2027, with no additional procedures for participants.
CONDITIONS
Brief Title
An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)
Research Team
B
Bayer Clinical Trials Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here